Forte Biosciences (FBRX) Insider Paul Wagner Buys 500,000 Shares

Paul Wagner, associated with Forte Biosciences, Inc., made a noteworthy move by purchasing 500,000 shares of the company on June 16, 2026. This insider transaction comes as Forte Biosciences' stock traded at $17.15 on the Nasdaq Capital Market.

Insider Buying and Selling at Forte Biosciences, Inc.

On June 16, 2026, Paul Wagner acquired 500,000 shares in Forte Biosciences, Inc. without a pre-set plan, indicating a personal decision to invest in the company. Other insiders have also been active, with Chief Financial Officer Riley Antony buying 22,000 shares on the same day. Additionally, several insiders, including Shivpreet Singh Kapoor and Richard Vincent, each purchased 18,353 shares on May 29, 2026.

Other Institutional Activity in Forte Biosciences

Among institutional investors, Federated Hermes, Inc. held steady with 1,765,516 shares worth approximately $45.7 million. Fred Alger Management, LLC reduced its stake by 187,006 shares to hold about 1,273,965 shares valued at $32.9 million. Janus Henderson Group PLC also trimmed its position by 237,725 shares, ending with 1,188,060 shares valued at $30.8 million. Meanwhile, Affinity Asset Advisors, LLC added 22,400 shares, bringing its total to 1,011,890 shares worth about $26.2 million.

Forte Biosciences, Inc. Stock Down 77.2%

Shares of Forte Biosciences, Inc. (NasdaqCM:FBRX) traded around $17.15. The company, with a market cap of approximately $360 million, isn't currently profitable, resulting in no meaningful P/E ratio. It has a beta of 2.871, indicating higher volatility compared to the broader market. The stock's 52-week range spans from $9.10 to $35.80, with a 50-day moving average of $24.24 and a 200-day moving average of $22.29.

Analysts Set New Price Targets

Analysts have shown interest in Forte Biosciences, maintaining a positive outlook. On November 25, 2025, Evercore ISI Group initiated coverage with a 'buy' rating and a $65.00 price target. Guggenheim also began coverage with a 'buy' rating and a $75.00 target on August 18, 2025. The consensus among four analysts is a 'buy' recommendation, with a mean target price of $63.75.

About Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Dallas, Texas. It focuses on developing therapies for autoimmune diseases, with its lead product candidate, FB-102, targeting conditions like celiac disease and vitiligo. The company is led by CEO Dr. Paul A. Wagner and employs 22 people.

Bottom Line

Paul Wagner's purchase of 500,000 shares underscores insider confidence in Forte Biosciences, Inc. Investors often monitor such transactions for potential insights into a company's prospects. While 13F filings and insider trades provide a historical snapshot, they may not reflect current positions or future performance.